BridgeBio

BridgeBio is a biopharmaceutical company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases and cancers. Their mission is to bridge the gap between promising genetic research and actual medicines, accelerating the process of translating scientific discoveries into patient solutions. Founded in 2015, they have built a diverse portfolio of 20+ drug development programs across various therapeutic areas, ranging from preclinical to late-stage development. Their company culture prioritizes patient needs, independent thinking, radical transparency, rapid execution, and scientific excellence, all while fostering a collaborative and data-driven environment.

BridgeBio operates a decentralized model that empowers program teams to focus on advancing science and helping patients. This structure is designed to eliminate bureaucracy and put decision-making power in the hands of those closest to the scientific research. They emphasize their commitment to diversity, equity, and inclusion, and they are expanding their global presence with offices in the United States, Canada, and Switzerland. With a strong emphasis on scientific innovation and collaboration, BridgeBio aims to deliver life-changing medicines to patients as quickly and safely as possible.

BridgeBio offers a flexible work environment with a hybrid model that allows employees to work from home and in the office. Many job postings specifically mention the ability to work remotely or from a hybrid location, indicating that flexible work arrangements are common. The company also offers flexible PTO, implying a supportive culture that values work-life balance.

BridgeBio offers a robust and market-competitive compensation and benefits package, including base pay, an annual performance bonus, company equity, and generous health benefits. Employees also enjoy flexible PTO, rapid career advancement for strong performers, the potential to work on multiple programs across various therapeutic areas, partnerships with leading institutions, and a commitment to Diversity, Equity & Inclusion.

BridgeBio is a commercial-stage biopharmaceutical company committed to developing transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers. Their mission focuses on bridging the gap between promising genetic research and actual medicines by creating a platform that rapidly translates scientific discoveries into patient solutions. This involves a decentralized corporate model that prioritizes focused execution, rigorous science, and a dedication to patient-centric care.

BridgeBio emphasizes a culture of scientific excellence, rapid execution, and a strong patient-centric focus. The company values its employees who are "Patient Champions," "Entrepreneurial Operators," "Truth Seekers," and individuals who "Inspire Excellence." BridgeBio operates in a collaborative, fast-paced, data-driven environment, where everyone is encouraged to perform at their best. The company prioritizes transparency, open communication, and decision-making power in the hands of those closest to the science.

BridgeBio is committed to fostering a diverse, equitable, and inclusive workplace. They actively promote a culture where individuals from all backgrounds feel welcome, respected, and valued. This commitment is reflected in their recruitment practices, employee development programs, and company-wide initiatives aimed at creating a sense of belonging for all employees.